Key result
Active antihypertensive agents (hydralazine, labetalol, methyldopa, minoxidil, prazosin) were more effective than placebo as third-line therapy, with hydralazine being the most generally suitable.
Why the study?
Does the addition of a third antihypertensive agent (hydralazine, labetalol, methyldopa, minoxidil, or prazosin) improve efficacy and acceptability in hypertensive patients inadequately controlled by a beta blocker and thiazide diuretic?
RCT (n=238)
random allocation
Does the addition of a third antihypertensive agent (hydralazine, labetalol, methyldopa, minoxidil, or prazosin) improve efficacy and acceptability in hypertensive patients inadequately controlled by a beta blocker and thiazide diuretic?
In patients with hypertension uncontrolled by a beta blocker and diuretic, adding hydralazine or prazosin offers the best balance of efficacy and acceptability compared to other agents or placebo.
No takes yet. Share an insight, caveat, or question.
May guide add-on selection in resistant hypertension on beta-blocker plus diuretic; leaves open relevance to current regimens and populations.
McAreavey et al. (1984) conducted an RCT in Hypertension (n=238). Hydralazine, labetalol, methyldopa, minoxidil, and prazosin vs. Placebo was evaluated on Acceptability and effectiveness. Active antihypertensive agents (hydralazine, labetalol, methyldopa, minoxidil, prazosin) were more effective than placebo as third-line therapy, with hydralazine being the most generally suitable.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: